Takara Bio Inc.

Takara Shuzo Co., Inc.

Nobuko Muraki

Ikunoshin Kato

Hiroaki Sagawa

Tatsuji Enoki

Mitsuko Ideno

Takahiro Marui

Kinuko Nagamine

Akiko Kato

Nobuto Koyama

Eiji Kobayashi

Katsushige Ikai

Hiromu Ohnogi

Fuyuko Takashima

Katsumi Sugiyama

Kinuko Ogawa

Masayuki Kishimoto

Shinji Okuda

The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.

Process for producing cytotoxic lymphocytes

A method for preparing lymphocytes characterized in that the method comprises the step of carrying out expansion in the presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand.

Method of producing lymphocytes

A method of producing lymphocytes characterized by comprising the step of culturing lymphocytes in the presence of a modified recombinant fibronectin fragment which has overlapping parts of the heparin-binding domain of fibronectin. This method makes it possible to achieve a high cell proliferation rate. The lymphocytes obtained thereby are appropriately usable in, for example, adoptive immunotherapy and, therefore, expected as highly useful in the clinical field. Moreover, a novel modified recombinant fibronectin fragment is provided.

The present invention relates to a chalcone compound represented by the following general formula: wherein Rand Rare taken together with the carbon atom to which they are bound, respectively, to form a hydroxydimethyl hexane ring, or where Ris a hydroxyl group, Ris an isohexenyl group, a derivative thereof, or a salt thereof. Also, the present invention relates to a therapeutic agent or prophylactic agent for a disease requiring neuronal protection, suppression for nitrogen monoxide (NO) production, inhibition for aldose reductase or suppression for interleukin production, and a food, beverage or feed for treatment or prevention of the above-mentioned disease, characterized in that each comprises the above-mentioned compound as an effective ingredient.

Chalcone compound

2,5-dihydroxytetrahydro-2-furancarboxylic acid represented by the following formula [I], its optically active substance or salt thereof. ##STR1##

Tetrahydrofurans

Growing community of inventors

Koka, Japan

Nobuko Muraki